Bax inhibitor peptide V5 (Synonyms: BIP-V5; BAX Inhibiting Peptide V5) |
| Catalog No.GC17195 |
A Bax inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 579492-81-2
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Bax inhibitor peptide V5 (BIP V5) is a peptide inhibitor of Bax translocation to mitochondria [1].
Bax is a pro-apoptotic member of Bcl-2 family proteins and plays an important role in mitochondria-dependent apoptosis. Bax stays in the cytosol and transfers into mitochondria after apoptotic stimuli [1].
BIP V5 is a membrane-permeable peptide inhibitor of Bax translocation to mitochondria. In HeLa cells, BIP V5 protected cells from UVC- and STS-induced apoptosis. In U87-MG glioma cells, MCF-7 breast cancer cells and LNCaP prostate cancer cells, BIP V5 also inhibited apoptosis induced by anti-cancer drugs cisplatin, etoposide and doxorubicin. While BIP V5 did not suppress UVC- or STS-induced apoptosis in Bax-deficient cells (DU145), which suggested BIP V5 only suppressed Bax-mediated apoptosis. Also, BIP (V5) inhibited Bax translocation to mitochondria stimulated by UVC irradiation and STS treatment. The caspase activation and the release of cytochrome c from mitochondria triggered by apoptotic stimuli were also significantly inhibited by BIP V5. BIP V5 inhibited the interaction of Ku70 and endogenous Bax in a dose-dependent way [1].
In a mouse model, BIP V5 increased expression of anti-apoptotic proteins XIAP and Bcl-2 by more than 11- and 3-fold and reduced expression of apoptosis-inducing proteins Bax, Bad, and nuclear factor-κ B-p65 by 10, 30, and nearly 50%, respectively. Also, BIP V5 increased glucose-responsive insulin secretion [2].
References:
[1]. Sawada M, Hayes P, Matsuyama S. Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70. Nat Cell Biol, 2003, 5(4): 352-357.
[2]. Rivas-Carrillo JD, Soto-Gutierrez A, Navarro-Alvarez N, et al. Cell-permeable pentapeptide V5 inhibits apoptosis and enhances insulin secretion, allowing experimental single-donor islet transplantation in mice. Diabetes, 2007, 56(5): 1259-1267.
| Cell experiment [1,2]: | |
|
Cell lines |
Mouse islet isolation |
|
Preparation method |
The solubility of this compound in DMSO is >24.1mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
0-100 μM, 24 h |
|
Applications |
Bax inhibitor peptide V5 (0-50 μM) reduced cell death in STF-cMyc cells but not in SW620 or NCI-H23 cells. BIP V5 does not result in any significant effect on cell cycle arrest at the G2/M phase. In mouse islet isolation, BIP V5 (100 μM) treatment upregulated expression of anti-apoptotic proteins Bcl-2 and XIAP by more than 3- and 11-fold and downregulated expression of apoptosis-inducing proteins Bax, Bad, and nuclear factor-κB-p65 by 10, 30, and nearly 50%, respectively. |
| Animal experiment [2]: | |
|
Animal models |
Streptozotocin-induced diabetic mice |
|
Dosage form |
100 μmol/l |
|
Application |
Following transplantation in streptozotocin-induced diabetic mice, 150 BIP V5-treated islet equivalents functioned as well as 450 control untreated islet equivalents in normalizing blood glucose. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Jo M J, Paek A R, Choi J S, et al. Regulation of cancer cell death by a novel compound, C604, in a c-Myc-overexpressing cellular environment[J]. European journal of pharmacology, 2015, 769: 257-265. [2]. Sawada M, Hayes P, Matsuyama S. Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70. Nat Cell Biol, 2003, 5(4): 352-357. [2].Rivas-Carrillo JD, Soto-Gutierrez A, Navarro-Alvarez N, et al. Cell-permeable pentapeptide V5 inhibits apoptosis and enhances insulin secretion, allowing experimental single-donor islet transplantation in mice. Diabetes, 2007, 56(5): 1259-1267. | |
| Cas No. | 579492-81-2 | SDF | |
| Synonyms | BIP-V5; BAX Inhibiting Peptide V5 | ||
| Chemical Name | (S)-6-amino-2-((Z)-((S)-2-((Z)-((S)-2-((Z)-(((S)-1-((S)-2-amino-3-methylbutanoyl)pyrrolidin-2-yl)(hydroxy)methylene)amino)-1-hydroxy-4-(methylthio)butylidene)amino)-1-hydroxy-4-methylpentylidene)amino)hexanoic acid | ||
| Canonical SMILES | CC(C[C@@](/N=C(O)/[C@](/N=C(O)/[C@]1([H])CCCN1C([C@](N)([H])C(C)C)=O)([H])CCSC)([H])/C(O)=N/[C@@](C(O)=O)([H])CCCCN)C | ||
| Formula | C27H50N6O6S | M.Wt | 586.79 |
| Solubility | ≥ 29.35mg/mL in DMSO, ≥ 91.4 mg/mL in Water | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7042 mL | 8.5209 mL | 17.0419 mL |
| 5 mM | 0.3408 mL | 1.7042 mL | 3.4084 mL |
| 10 mM | 0.1704 mL | 0.8521 mL | 1.7042 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *